Vogel A, Qin S, Kudo M, et al. - Researchers focused on the impact of treatment with lenvatinib vs sorafenib on health-related quality of life (HRQOL) of patients suffering from hepatocellular carcinoma. The efficacy as well as the safety of lenvatinib vs sorafenib as a first-line systemic treatment for unresectable hepatocellular carcinoma was compared in a previously published multicentre, randomised, open-label, non-inferiority phase 3 study (REFLECT). Assessment of patient-reported outcomes (PROs), obtained at baseline, on day 1 of each subsequent cycle, and at the completion of treatment, was performed in post-hoc analyses of secondary and exploratory endpoints in the analysis population, which was the subpopulation of patients with a PRO evaluation at baseline. Nominally statistically significant delays in definitive, meaningful deterioration on the Quality of Life Questionnaire Core 30 fatigue, pain, and diarrhoea domains was observed in patients who received treatment with lenvatinib vs those administered sorafenib. Findings indicate that HRQOL represents a crucial therapeutic consideration for patients receiving treatment for unresectable hepatocellular carcinoma. The administration of lenvatinib vs sorafenib to delay functional deterioration in advanced hepatocellular carcinoma is supported by the evidence of HRQOL advantages in clinically meaningful domains.